Targeted approaches in the treatment of osteoporosis: Differential mechanism of action of denosumab and clinical utility

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 253-266

  Cavalli, Loredana ^a   Brandi, Maria Luisa ^a  

^a Department of Internal Medicine   (Italy)

Author keywords

Antibody; BMD; Denosumab; Osteoporosis; RANK L; Targeted therapy

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CONJUGATED ESTROGEN; DENOSUMAB; ESTROGEN DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL INFECTION; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE DESTRUCTION; BONE TURNOVER; CELL ACTIVITY; CELLULITIS; CORTICAL BONE; DERMATITIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EAR INFECTION; ECZEMA; ENDOCARDITIS; FRAGILITY FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HOT FLUSH; HUMAN; HYPOCALCEMIA; INJECTION SITE REACTION; JAW OSTEONECROSIS; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVIEW; RISK REDUCTION; SIDE EFFECT; SKIN INFECTION; SPINE FRACTURE; TRABECULAR BONE; URINARY TRACT INFECTION;

EID: 84875334647     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s7688     Document Type: Review

References (101)

1. Cavalli L, Brandi ML. Age- and gender-related macro and microarchitecture changes in bone structure and implications for treatment. Int J Clin Rheumatol. 2011;6(3):359-369.
2. Bouxsein ML. Determinant of skeletal fragility. Best Pract Res Clin Rheumatol. 2005;19(6):897-911.
3. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108-1112.
4. Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010;87(6):469-484.
5. Chen P, Miller PD, Recker R, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res. 2007; 22(8):1173-1180.
6. Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford). 2009;48 Suppl 4:iv3-iv8.
7. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res. 2005;20(2):177-184.
8. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res. 2004;19(12):2012-2020.
9. Fuchs RK, Allen MR, Condon KW, et al. Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int. 2008;19(9):1331-1341.
10. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis: an age-related and gender-specific disease - a mini-review. Gerontology. 2009;55(1):3-12.
11. Cummings SR. How drugs decrease fracture risk: lessons from trials. J Musculoskelet Neuronal Interact. 2002;2(3):198-200.
12. Beck TJ, Stone KL, Oreskovic TL, et al. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures. J Bone Miner Res. 2001;16(11):2103-2110.
13. Reszka AA, Rodan GA. Bisphosphonates mechanism of action. Curr Osteoporos Rep. 2003;1(2):45-52.
14. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2-19.
15. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15(8): 1467-1476.
16. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999;274(49):34967-34973.
17. Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. 2001;29(6):553-559.
18. Rogers HL, Marshall D, Rogers MJ. Effects of bisphosphonates on osteoclasts in vitro, studies by scanning electron microscopy. Bone. 2002;30(3):43S.
19. Alakangas A, Selander K, Mulari M, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int. 2002;70(1):40-47.
20. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335(14):1016-1021.
21. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci. 1997;42(2):281-288.
22. Elliott SN, McKnight W, Davies NM, et al. Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci. 1998;62(1): 77-91.
23. Peter CP, Kindt MV, Majka JA. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci. 1998;43(5): 1009-1015.
24. Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res. 2009;37(2):407-416.
25. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155.
26. Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD004523.
27. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
28. Chesnut CH III, Skag A, Christiansen C, et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249.
29. Recker R, Masarachia P, Santora A, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin. 2005;21(2):185-194.
30. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int. 2003;73(5):423-432.
31. Seeman E. To stop or not to stop, that is the question. Osteoporos Int. 2009;20(2):187-195.
32. Reginster JY, Bruyère O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone. 2009;45(6):1059-1064.
33. European Medicines Agency. Protelos: scientific discussion. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000560/human_med_000999.jsp&jsenabled=true. Accessed October 12, 2009.
34. Deeks ED, Dhillon S. Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis. Drugs. 2010;70(6):733-759.
35. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 2001;69(3): 121-129.
36. Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol. 2009;157(7):1291-1300.
37. Zhu LL, Zaidi S, Peng Y, et al. Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun. 2007;355(2):307-311.
38. Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol. 2007;74(3):438-447.
39. Caverzasio J. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone. 2008;42(6): 1131-1136.
40. Fromiguè O, Hay E, Barbara A, et al. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med. 2009;13(8B):2189-2199.
41. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Eng J Med. 2004;350(5):459-468.
42. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816-2822.
43. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year randomized, placebo-controlled trial. Atrthritis Rheum. 2008;58(6):1687-1695.
44. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359(9322):2018-2026.
45. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009;24(8):1358-1368.
46. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need of a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res. 2005;20(2):177-184.
47. Recker RR, Bare SP, Smith SY, et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone. 2009;44(1): 113-119.
48. Miyakoshi N. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr Pharm Des. 2004;10(21):2615-2627.
49. Adami S, Brandi ML, Canonico PL, Minisola G, Minisola S, Tarantino U. Appropriate use of anabolic treatment for severe osteoporosis. Clin Cases Miner Bone Metab. 2010;7(2):114-122.
50. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-1199.
51. Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009;94(7):2495-2501.
52. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS). J Bone Miner Res. 2009;24(4):726-736.
53. Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging. 2011;6:151-160.
54. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res. 2008;23(12):1923-1934.
55. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23(4):525-535.
56. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95(11):1046-1057.
57. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas. 2010;66(2):182-186.
58. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999; 96(7):3540-3545.
59. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165-176.
60. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-319.
61. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145(3): 527-538.
62. Mosekilde L, Sogaard CH, Danielsen CC, Torring O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology. 1991;129(1):421-428.
63. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157(2): 435-448.
64. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490-495.
65. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
66. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139(3):1329-1337.
67. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142(12):5050-5055.
68. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998; 95(7):3597-3602.
69. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390(6656):175-179.
70. Mizuno A, Kanno T, Hoshi M, et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab. 2002;20(6):337-344.
71. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221-1230.
72. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7): 1059-1066.
73. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-831.
74. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12): 1832-1841.
75. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2): 222-229.
76. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
77. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149-2157.
78. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-161.
79. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1): 72-81.
80. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone. 2010; 47(1):34-40.
81. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev. 2005;208:207-227.
82. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev. 2005;208:19-29.
83. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13(18): 2412-2424.
84. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-323.
85. Reid IR, Benhamou CL, Bolognese M, et al. Effects of denosumab on bone histology and histomorphometry: the FREEDOM and STAND studies [abstract]. J Bone Miner Res. 2009;24(Suppl 1):S9.
86. United States Food and Drug Administration, Amgen Inc. Briefing information for the August 13, 2009 meeting of the Reproductive Health Drugs Advisory Committee. 2009. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/ucm176584.htm. Accessed October 30, 2009.
87. Lee RJ, Saylor PL, Smith MR. Treatment and prevention of bone complication from prostate cancer. Bone. 2011;48(1):88-95.
88. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221-1228.
89. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28): 4431-4437.
90. Deodhar A, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2010;62(4):569-574.
91. Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med. 2009;361(8):818-820.
92. Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res. 2009;41(10): 721-729.
93. Kyrgidis A, Toulis KA. Denosumab-related osteonecrosis of the jaws. Osteoporos Int. 2011;22(1):369-370.
94. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl. 2009; 7(3):12.
95. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer Suppl. 2009; 7(3):2-3.
96. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med. 2008;121(6):475-483.
97. Kyrgidis A, Vahtsevanos K. Osteonecrosis of the jaw in patients receiving oral bisphosphonates. Osteoporos Int. 2010;21(3):535-536.
98. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008;9(12):1166-1172.
99. Kyrgidis A, Vahtsevanos K. "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws. Clin Oral Investig. 2009;13(4): 479-480.
100. Gordon D. Denosumab increases bone density, no atypical fracture risk. In: Medscape Medical News [website on the Internet]. November 10, 2011. Available from: http://www.medscape.com/viewarticle/753389. Accessed January 17, 2012.
101. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003;5(1):65-74.